1 In 4 Adults Worldwide Eligible For GLP-1 Treatment For Obesity

An estimated 27% of adults worldwide were eligible to receive a glucagon-like peptide-1 (GLP-1) receptor agonist (approximately 799 million individuals). Of these individuals, 34.6% were eligible due to the presence of hypertension or diabetes, or both, for individuals with a body mass index (BMI) of 27 kg/m² or more (or BMI ≥24 kg/m² in Asia).

Researchers analyzed data from nationally representative cross-sectional household health surveys conducted in 99 countries between 2008 and 2021 for 810,635 non-pregnant individuals age 25 to 64 years. Individuals were defined as eligible for GLP-1 receptor . . .